Ads
related to: eye drops for ocular hypertension treatment options side effects weight gain
Search results
Results From The WOW.Com Content Network
Ocular hypertension is treated with either medications (eye drops), surgery, or laser. Treatment, by lowering the intraocular pressure, may help decrease the risk of vision loss and damage to the eye from glaucoma. Treatment options include pressure-lowering 'antiglaucomatous' eye drops, surgery, and/or laser eye surgery. [4]
Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye (intraocular pressure). [5] This includes ocular hypertension and open-angle glaucoma. [5] Latanaprost is applied as eye drops to the eyes. [5] Onset of effects is usually within four hours, and they last for up to a day. [5]
Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma. [3] It is used as an eye drop. [3] Effects begin within three hours and last for at least eight hours. [3] It is also available as the combination dorzolamide/timolol. [3] [4]
Bimatoprost/timolol, sold under the brand name Ganfort, is a medication for the treatment of certain conditions involving high pressure in the eyes, specifically open angle glaucoma and ocular hypertension. [1] [3] It is available as eye drops. [1] [3] It was approved for medical use in the European Union in May 2006. [3]
Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. [1] [2] [3] In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.
Specifically, the mean reduction in intraocular pressure was 27.4% for the combination product, 15.5% for dorzolamide 2%, and 22.2% for timolol 0.5%. Compared to other products such as latanoprost, both are equally efficacious with regard to lowering intraocular pressure and getting patients to reach their target intraocular pressure. [14]